Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adenoviral vaccine encoding wild-type Trop2
- Development stage
- Preclinical
- Lead developer
- Duke University
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Subcutaneous
01
Overview
Adenoviral vaccine encoding wild-type Trop2 (Ad-Trop2 WT) is a preclinical cancer vaccine developed by researchers at Duke University. The vaccine utilizes an adenoviral vector to deliver the gene encoding wild-type trophoblast cell-surface antigen 2 (Trop2), a cell-surface glycoprotein overexpressed in various epithelial cancers. By expressing the wild-type Trop2 antigen, the vaccine is designed to stimulate robust humoral and cellular immune responses, including the production of class-switched IgG antibodies and activation of myeloid cells, to target and eliminate Trop2-expressing tumor cells.
- Other names
- adenoviral vaccine encoding wild-type TROP2adenovirus-encoded wild-type Trop2 vaccine
02
Targets
CD4 (T lymphocyte surface antigen)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on adenoviral vaccine encoding wild-type Trop2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adenoviral vaccine encoding wild-type Trop2.